Cargando…

Rituximab: Failed to develop anti-SARS-Cov-2 antibodies: case report

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642175/ http://dx.doi.org/10.1007/s40278-021-06700-3

Ejemplares similares

Rituximab: SARS-CoV-2 pneumonia: case report
Publicado: (2021)

Rituximab: Reactivation of SARS-CoV-2 infection: case report
Publicado: (2021)

Rituximab: Reactivation of SARS-CoV-2 infection: case report
Publicado: (2021)

Leflunomide/rituximab: SARS-CoV-2 infection: case report
Publicado: (2021)

Convalescent-anti-sars-cov-2-plasma/rituximab/unspecified steroids: Fever and lymphodepletion: 2 case reports
Publicado: (2021)

Ocrelizumab/rituximab: SARS-CoV-2 infection: 2 case reports
Publicado: (2021)

Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma
por: Yasuda, Hajime, et al.
Publicado: (2020)

Prednisolone/rituximab: COVID-19 and SARS-CoV-2 pneumonia: case report
Publicado: (2021)

Bendamustine/rituximab: Prolonged SARS-CoV-2 viral shedding : case report
Publicado: (2022)

Case Report: Unremitting COVID-19 Pneumonia, Viral Shedding, and Failure to Develop Anti-SARS-CoV-2 Antibodies for More Than 6 Months in Patient with Mantle Cell Lymphoma Treated with Rituximab
por: Berktas, Bahadir M., et al.
Publicado: (2022)

Initial seronegative immune-mediated necrotising myopathy with subsequent anti-HMGCR antibody development and response to rituximab: case report
por: Thomas, Rhys, et al.
Publicado: (2020)

Convalescent-anti-sars-cov-2-plasma/dexamethasone/rituximab: Depletion of B-lymphocytes, lack of efficacy and off label treatment: case report
Publicado: (2022)

Mycophenolate mofetil/prednisolone/rituximab: SARS-CoV-2 infection and lack of efficacy: 2 case reports
Publicado: (2022)

Development and characterization of an anti-rituximab monoclonal antibody panel
por: Tada, Minoru, et al.
Publicado: (2018)

Dexamethasone/prednisone/rituximab: Prolonged SARS-CoV-2 infection and off-label use: case report
Publicado: (2022)

Cefepime/convalescent-anti-sars-cov-2-plasma/rituximab: Relapsed COVID-19 and lack of efficacy following off-label use: 2 case reports
Publicado: (2022)

SARS-CoV-2 and Anti-Cardiolipin Antibodies
por: Jizzini, Mazen, et al.
Publicado: (2020)

Rituximab: Hypogammaglobulinaemia: 2 case reports
Publicado: (2021)

Convalescent-anti-SARS-CoV-2-plasma/remdesivir/rituximab: COVID-19 infection, and lack of efficacy following off-label use: 20 case reports
Publicado: (2022)

Rituximab: No antibody response post COVID-19 vaccination: case report
Publicado: (2021)

Recovery from severe persistent COVID-19 without evidence of an anti-SARS-CoV-2 antibody response in a man with mantle cell lymphoma treated with rituximab
por: Horiuchi, Hiroshi, et al.
Publicado: (2022)

Combination therapy with rituximab and cyclophosphamide in the treatment of anti-neutrophil cytoplasmic antibodies (ANCA) positive pulmonary hemorrhage: case report
por: Baird, Emily M, et al.
Publicado: (2011)

Bendamustine/remdesivir/rituximab: Emergence of drug resistance and SARS-CoV-2 viraemia due to B-cell immunodeficiency : case report
Publicado: (2021)

Case Report of COVID-19 after Full Vaccination: Viral Loads and Anti-SARS-CoV-2 Antibodies
por: Komiazyk, Magdalena, et al.
Publicado: (2021)

Rituximab: COVID-19: 2 case reports
Publicado: (2021)

Rituximab: COVID-19: 2 case report
Publicado: (2021)

Rituximab: COVID-19: 2 case reports
Publicado: (2022)

Emergence of SARS-CoV-2 resistance mutations in a patient who received anti-SARS-COV2 spike protein monoclonal antibodies: a case report
por: Fenaux, Honorine, et al.
Publicado: (2021)

Posterior scleritis with anti-neutrophil cytoplasmic antibody-associated vasculitis utilizing rituximab therapy to maintain remission: A case report
por: Weng, Xinyu, et al.
Publicado: (2022)

Long COVID treated successfully with antivirals in a rituximab-treated follicular lymphoma patient with persistent negative-antibodies to SARS-CoV2
por: Tayar, Elias, et al.
Publicado: (2023)

Development of anti-rituximab antibodies in rituximab-treated patients: Related parameters & consequences
por: Saffari, Fatemeh, et al.
Publicado: (2022)

A case of transient existence of SARS-CoV-2 RNA in the respiratory tract with the absence of anti-SARS-CoV-2 antibody response
por: Lin, Yi-Chun, et al.
Publicado: (2020)

Anti-SARS-CoV-2 Antibody Level among Renal Transplant Recipients: A Case Report from Nepal
por: Ranabhat, Kamal, et al.
Publicado: (2022)

Rituximab: COVID-19 infection: 2 case reports
Publicado: (2020)

Rituximab: COVID-19 infection: 2 case reports
Publicado: (2022)

Discrepant Antigen-specific Antibody Responses Causing SARS-CoV-2 Persistence in a Patient Receiving B-cell-targeted Therapy with Rituximab
por: Takakuwa, Teruhito, et al.
Publicado: (2021)

Convalescent-anti-SARS-CoV-2-plasma: Ecchymosis: case report
Publicado: (2022)

Rituximab: COVID-19: case report
Publicado: (2021)

Rituximab: Humoral immunodeficiency: case report
Publicado: (2021)

Rituximab: Serum sickness: case report
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u53v5f6rkn95704a248cdluj7d